Statements Author contributions TS, CK, and CS all contributed to the design, writing, and editing of the manuscript
Peptide Vials (GHK-Cu, 50 mg each): 5 days/week (1.0-2.0 mg/day): 8 weeks (~50 mg total): 1 vial 12 weeks (~90 mg total): 2 vials 16 weeks (~130 mg total): 3 vials 3 times/week (2 mg each): 8 weeks (~48 mg total): 1 vial 12 weeks (~72 mg total): 2 vials 16 weeks (~96 mg total): 2 vials Insulin Syringes (U-100, 29-31 gauge): 5 days/week: Per week: 5 syringes 8 weeks: 40 syringes 12 weeks: 60 syringes 16 weeks: 80 syringes 3 times/week: Per week: 3 syringes 8 weeks: 24 syringes 12 weeks: 36 syringes 16 weeks: 48 syringes Sterile or Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for the displayed calculation
Simple timing framework Baseline Discuss baseline labs before starting or changing dose, especially with diabetes, kidney disease, pancreatitis history, gallbladder history, thyroid cancer history, or major calorie restriction
I would recommend Svelte strongly
The nuclear factor erythroid 2-related factor 2 ( NFE2L2 or NRF2) transcription factor is constitutively activated in many cancers and promotes a specific gene expression program involved in cellular detoxification, redox buffering, and metabolic rewiring (Cancer Genome Atlas Research, 2012